Johnson & Johnson (UKEX:JNJ) Other Net Income (Loss) : ₴858,093 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Johnson & Johnson Other Net Income (Loss)?

Johnson & Johnson's Other Net Income (Loss) for the three months ended in Dec. 2023 was ₴-3,292 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was ₴858,093 Mil.

Johnson & Johnson's quarterly Other Net Income (Loss) increased from Jun. 2023 (₴0 Mil) to Sep. 2023 (₴861,385 Mil) but then declined from Sep. 2023 (₴861,385 Mil) to Dec. 2023 (₴-3,292 Mil).

Johnson & Johnson's annual Other Net Income (Loss) declined from Dec. 2021 (₴122,035 Mil) to Dec. 2022 (₴62,307 Mil) but then increased from Dec. 2022 (₴62,307 Mil) to Dec. 2023 (₴865,669 Mil).

Johnson & Johnson Other Net Income (Loss) Historical Data

The historical data trend for Johnson & Johnson's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Other Net Income (Loss) Chart

Johnson & Johnson Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

122,035.19

62,306.56

865,668.53

Johnson & Johnson Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	861,385.21	-3,291.82	-

Johnson & Johnson Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₴858,093 Mil.

Johnson & Johnson Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson (UKEX:JNJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (UKEX:JNJ) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

JNJ:USA JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK 0R34:UK JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Austria JNJ:Argentina

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.